×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KURA – kura oncology, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KURA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/21
10:38 am
kura
Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]
Medium
Report
Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]
12/20
03:22 am
kura
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]
Medium
Report
How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]
12/19
07:50 pm
kura
Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]
Medium
Report
Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]
12/8
10:30 am
kura
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Low
Report
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
12/6
09:21 pm
kura
Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]
Low
Report
Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]
12/5
07:21 am
kura
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/4
08:12 am
kura
Kura Oncology: A Cautious Buy [Seeking Alpha]
Low
Report
Kura Oncology: A Cautious Buy [Seeking Alpha]
12/3
07:02 pm
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
04:30 pm
kura
Form 4 Kura Oncology, Inc. For: Dec 18 Filed by: Burrows Francis
High
Report
Form 4 Kura Oncology, Inc. For: Dec 18 Filed by: Burrows Francis
12/18
04:07 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Burrows Francis
Low
Report
Form 144 Kura Oncology, Inc. Filed by: Burrows Francis
12/10
04:05 pm
kura
Form 4 Kura Oncology, Inc. For: Dec 09 Filed by: Hasnain Faheem
Low
Report
Form 4 Kura Oncology, Inc. For: Dec 09 Filed by: Hasnain Faheem
12/9
04:23 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Hasnain Faheem
Low
Report
Form 144 Kura Oncology, Inc. Filed by: Hasnain Faheem
12/2
08:10 am
kura
Form 8-K Kura Oncology, Inc. For: Dec 02
Medium
Report
Form 8-K Kura Oncology, Inc. For: Dec 02
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie
11/14
08:00 pm
kura
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: FORD KATHLEEN
Medium
Report
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: FORD KATHLEEN
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock.
41.3%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
TOP News Decliners
3/17
Kura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - Slideshow [Seeking Alpha]
-14.5%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: